{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106235","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.337605+00:00","generated_at":"2026-05-17T15:09:36.358123+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agenus Q2 net loss improves; Zydus deal adds $91M; BOT/BAL Phase 3 starts Q4 2025","bullets":["Q2 revenue $25.7M; YTD net loss $56.4M vs $118.3M YoY; cash burn reduced to $45.8M from $76.4M.","Zydus collaboration closing Q3 2025; $91M upfront capital to support development and regulatory activities.","BOT/BAL: 42% two-year survival in refractory MSS CRC; FDA agreed to streamlined Phase 3 (BATTMAN) starting Q4 2025.","Virtual stakeholder meeting on August 27, 2025 to review Q2 results and strategic progress.","Noetik AI partnership started to refine patient selection via AI algorithms."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106235","json":"https://secwatch.observer/filing/0000950170-25-106235.json","markdown":"https://secwatch.observer/filing/0000950170-25-106235.md","text":"https://secwatch.observer/filing/0000950170-25-106235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/0000950170-25-106235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/agen-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:09:36.358123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}